Raredr

US Military Members Diagnosed with Keratoconus Become First Patients Treated with Ophthalmic Therapy

Andrew Black
Published Online: Wednesday, Jan 11, 2017
Military Service Members diagnosed with keratoconus located in the Fort Belvoir Hospital, located in Virginia became the first patients treated with the only FDA approved corneal cross-linking procedure. Keratoconus previously had no surgical treatment available. 
 
Before Avedro’s cross-linking treatment procedure, keratoconus patients were forced to wear specialized contact lenses. This caused major issues for those serving in the military because contact lenses aren’t approved for combat. With the new treatment procedure, this is no longer a problem.
 
The corneal collagen cross-linking is designed with Avedro’s Photrexa Viscous, Photrexa and the KXL system. Photrexa Viscous, Photrexa are photoenhancers indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.
 
Avedro’s corneal cross-linking procedure was approved in April 2016.

About keratoconus

Keratoconus is a rare condition in which the cornea thins and gradually bulges outward into a cone shape.
 
Corneal ectasia is a rare outcome of lasik or photorefractive keratectomy surgery. It can begin within a week of surgery or after several years and is associated with worsening best-uncorrected visual acuity, an increase in ocular aberrations, and decreasing best-corrected distance visual acuity. It can lead to vision loss.

To stay informed on the latest in rare disease news and developments, please sign up for our weekly newsletter at www.raredr.com/newsletter


Latest Articles
47-year-old BethAnn Telford will run 7 marathons on 7 continents in 7 days. In 2005, she was diagnosed with brain cancer.
In honor of our annual AHC Day, AHCF is excited to announce that we will be able to fund two research projects to get us one step closer to a treatment for AHC!
Tesaro has opened up an expanded access program (EAP) for their PARP inhibtor, niraparib for ovarian cancer patients.
Saad Usmani, MD, FACP, of the Levine Cancer Institute talks about the convenience and safety of subcutaneous delivery of daratumumab in multiple myeloma patients.
$vacMongoViewPlus$ $vAR$